Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2024 Earnings Conference Call May 14, 2024 8:00 AM ET

Company Participants

Alex Braun - Vice President & Head of Investor Relations
Daniel O’Connell - Chief Executive Officer
Matt Zuga - Chief Financial Officer & Chief Business Officer
Eric Siemers - Chief Medical Officer

Conference Call Participants

Tom Shrader - BTIG
Samantha Schaeffer - Cantor Fitzgerald
Jason Zemansky - Bank of America

Operator

Good day and thank you for standing by. Welcome to Acumen Pharmaceuticals First Quarter 2024 Conference Call and Webcast. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Alex Braun, Vice President and Head of Investor Relations. Please go ahead.

Alex Braun

Thanks, Norma. Good morning and welcome to the Acumen conference call to discuss our business update and financial results for the quarter ended March 31, 2024. With me today are Dan O'Connell, our CEO; and Matt Zuga, our CFO and Chief Business Officer. Dan and Matt has some prepared remarks and then we'll open the call for questions. Joining for the Q&A session, we also have Dr. Jim Doherty, our President and Chief Development Officer; and Dr. Eric Siemers, our Chief Medical Officer.

Before we begin, we encourage listeners to go to the Investors section of the Acumen website to find our press release issued this morning that we'll discuss today. Please note that during today's conference call, we may make forward-looking statements within the meaning of the federal securities laws, including statements concerning our financial outlook and expected business plans. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Please see Slide 2 of our corporate presentation, our press release issued this morning and our most recent annual and quarterly reports filed with the SEC for important risk factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise the information provided on this call or in the accompanying presentation as a result of new information or future results or developments.

And with that, I'll turn the call over to Dan.

Daniel O’Connell

Thanks, Alex. Good morning, everyone and thanks for joining us today.

As we noted on our year-end call in March, 2024 is a year of execution for Acumen as we work to establish the therapeutic potential of sabirnetug as a best-in-class treatment option for the substantial early Alzheimer's patient population. I'm pleased to say that we are off to a great start with the first patient dosed in our ALTITUDE-AD Phase II study announced just last week. ALTITUDE is a randomized placebo-controlled double-blind study with 3 arms designed to evaluate the clinical efficacy and safety of sabirnetug with approximately 180 participants per arm for a total of 540 participants which with MCI or mild dementia due to Alzheimer's disease. We are highly encouraged by the start of the ALTITUDE study which we attribute to a couple of key factors. First, we received positive feedback from site investigators on our Phase I INTERCEPT results. The thoroughness of the INTERCEPT data package appears to be resonating, particularly the confluence of biomarker improvements we saw in patients after only 3 doses.